Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer

医学 癌症 内科学 耐受性 肿瘤科 无容量 化学免疫疗法 胃肠病学 免疫疗法 不利影响
作者
Zev A. Wainberg,Yoon‐Koo Kang,Keun‐Wook Lee,Seung Tae Kim,Joseph Chao,Daniel V.T. Catenacci,Sung Yong Oh,Heloisa Prado Soares,Jennifer Eva Selfridge,Yongjun Cha,Roland T. Skeel,Hyung‐Don Kim,Anh Tuan Tran,Achim K. Moesta,Tracy dela Cruz,Anil K. Singhal,Thomas Michael Jahn,Farshid Dayyani
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): CT015-CT015 被引量:9
标识
DOI:10.1158/1538-7445.am2022-ct015
摘要

Abstract Background: The ecto-ATPase CD39 is the rate-limiting enzyme in the adenosine pathway that plays an important immune regulatory role. Preclinically, inhibition of CD39 by TTX-030, a first-in-class fully human anti-CD39 antibody, reversed immunosuppression by maintaining high levels of immune-stimulatory extracellular ATP while reducing suppressive adenosine. The addition of nivolumab to chemotherapy has recently become the standard of care of 1st-line (1L) treatment of locally advanced or metastatic (LA/M) gastric cancer but further improvements are needed. Methods: An expansion cohort of Study TTX-030-002 (ongoing, US and South Korea) is evaluating the safety and efficacy of the combination of TTX-030, budigalimab (anti-PD-1) and FOLFOX for the 1L treatment of patients (pts) with LA/M HER2− gastric/GEJ adenocarcinoma. The primary objective was to assess safety and tolerability. Secondary endpoints included ORR by RECIST/iRECIST, and PFS. Correlative studies included the analysis of intratumoral expression of CD39 and PD-L1. Results: Forty-four pts were enrolled with the median age [range] of 61 [30−81] years, 41% were female, and 57% were Asian. Pts had an ECOG of 0 (39%) or 1 (61%), 70% had gastric adenocarcinoma, 30% had GEJ adenocarcinoma. As of the safety data cutoff (Nov 19, 2021), 39 pts (89%) experienced at least 1 treatment-emergent AE (any Grade, regardless of relatedness). Twenty-one pts (48%) experienced at least 1 AE considered related to TTX-030 (any Grade); five (11%) experienced a Grade 3/4 AE considered related to TTX-030. There were no Grade 5 TEAEs. Eleven pts (25%) had experienced SAEs; none were considered related to TTX-030. The most common AEs by preferred term (any Grade, regardless of relatedness) in ≥10 pts were nausea (52%), neutrophil count decreased (39%), decreased appetite (30%), diarrhea (25%), and fatigue (23%). The most common Grade ≥3 AEs (regardless of relatedness) in ≥2 pts were neutrophil count decreased (27%), febrile neutropenia (5%), hypokalemia (5%). As of the efficacy data cutoff (Dec 2, 2021), the median time [range] on study was 139 [8−375] days. Among 38 efficacy evaluable pts, 23 pts experienced PR or better as best response (PR: n=21; CR: n=2; ORR=61%), 12 experienced SD, and 3 had PD. Thirty-six of the 38 efficacy-evaluable patients had known PD-L1 Combined Positive Score (CPS); response rates were 4/10 (CPS <1), 8/10 (CPS ≥1 and <5), and 11/16 (CPS ≥ 5). Conclusions: Preliminary results indicate that the combination of TTX-030, budigalimab and FOLFOX exhibited promising efficacy as 1L treatment of LA/M gastric/GEJ cancer regardless of CPS status and has a manageable safety profile without evidence of excessive toxicities. To our knowledge, this represents the first report of an anti-CD39 antibody in combination with chemo-immunotherapy in gastric cancer. Updated clinical and biomarker data will be included in the final presentation. Citation Format: Zev Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Seung Tae Kim, Joseph Chao, Daniel Catenacci, Sung Yong Oh, Heloisa P. Soares, J. Eva Selfridge, Yongjun Cha, Roland T. Skeel, Hyung-Don Kim, Anh Tran, Achim Moesta, Tracy Dela Cruz, Anil Singhal, Thomas M. Jahn, Farshid Dayyani. Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT015.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔的应助被郭益通采纳,获得10
刚刚
荷序完成签到,获得积分20
刚刚
刚刚
Xxiinp发布了新的文献求助10
刚刚
刚刚
sciq完成签到,获得积分10
1秒前
潘多拉完成签到,获得积分10
1秒前
尊敬跳跳糖完成签到,获得积分10
1秒前
1秒前
2秒前
天一晴完成签到 ,获得积分10
2秒前
2秒前
3秒前
大模型的应助被dragon采纳,获得10
3秒前
充电宝的应助被马也采纳,获得10
4秒前
2319374525发布了新的文献求助10
4秒前
tana98906完成签到 ,获得积分10
4秒前
5秒前
鲤鱼秋尽完成签到 ,获得积分10
5秒前
iiing完成签到,获得积分10
5秒前
Mr.egg发布了新的文献求助10
5秒前
侠客岛完成签到,获得积分10
5秒前
yy完成签到,获得积分10
5秒前
Charles完成签到 ,获得积分10
5秒前
acacxhm7完成签到 ,获得积分10
6秒前
所所的应助被qingzheng1019采纳,获得10
6秒前
kobe发布了新的文献求助10
6秒前
尹山蝶完成签到,获得积分0
6秒前
sincyking完成签到,获得积分10
6秒前
Jimmy Ko发布了新的文献求助10
6秒前
科研通AI6.3的应助被无字诉题采纳,获得10
7秒前
7秒前
限量版小祸害完成签到 ,获得积分10
7秒前
基金中中中完成签到,获得积分10
7秒前
顺利的莺发布了新的文献求助10
8秒前
成就飞莲完成签到,获得积分10
8秒前
FFXXFF完成签到,获得积分10
8秒前
哈哈完成签到,获得积分10
9秒前
开心的兔子完成签到,获得积分20
9秒前
ZM发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105